RETATRUTIDE (20mg)

This 20mg presentation of retatrutide supports advanced or extended-phase research protocols. As the most potent GLP-1/GIP/glucagon triple agonist under current investigation, retatrutide at higher study concentrations has yielded the most significant body weight reductions recorded in peer-reviewed pharmaceutical trials to date.

Mechanism of Action

•        Triple receptor agonism of GLP-1, GIP, and glucagon receptors produces complementary metabolic effects in research models.

•        Studied for profound appetite modulation through GLP-1 and GIP pathways, with sustained energy expenditure through glucagon activation.

•        Research shows improved insulin sensitivity and fasting glucose normalization in metabolic studies.

•        Investigated for hepatic fat reduction and visceral adipose mobilization in extended study models.

Research Areas

•        Advanced obesity pharmacology at escalating dose concentrations.

•        Progressive weight loss plateau studies requiring higher compound concentrations.

•        Long-term metabolic stabilization research following significant weight reduction.

Presentation and Storage

Supplied as a lyophilized powder in a sealed vial containing 20mg of retatrutide. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.